[EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS [FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE JAK2
[EN] BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE BIARYLE ACÉTAMIDE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:AMBIT BIOSCIENCES CORP
公开号:WO2015031613A1
公开(公告)日:2015-03-05
Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.
HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS
申请人:VITAS PHARMA RESEARCH PRIVATE LIMITED
公开号:US20140249170A1
公开(公告)日:2014-09-04
The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.
这项发明涉及一种新型杂环化合物,可以特异性地抑制细菌FabI,并可用于治疗葡萄球菌感染。
[EN] PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS<br/>[FR] INHIBITEURS DE RAF DE PYRAZOLE[3,4-B]PYRIDINE
申请人:ARRAY BIOPHARMA INC
公开号:WO2009111279A1
公开(公告)日:2009-09-11
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
A compound represented by general formula (I-a) : has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.